Skip to content
Sign in
Artwork for OncoPharm
OncoPharm · May 28 · 13 min

Pivekimab sunirine

Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what the heck is BPDCN? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

0:00-13:49
Play in

transcript

No transcript — this publisher did not publish one.

show notes

Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what the heck is BPDCN?

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

more episodes

All episodes